Vitamin D Biology

Pediatric Bone

Volumn , Issue , 2012, Pages 163-187

  St Arnaud, René A ^a   Demay, Marie B ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882912330     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-382040-2.10008-5     Document Type: Chapter

References (281)

1. McCollum E.V., Simmonds N., Becker J.E., Shipley P.G. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922, 53:293-298.
2. Steenbock H., Black A. Fat-soluble vitamins. XVII. The induction of growth-promoting and calcifying properties in a ration by exposure to ultraviolet light. J Biol Chem 1924, 61:405-422.
3. Holick M.F. Photobiology of vitamin D. Vitamin D 1997, 33-39. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
4. Fukushima M., Suzuki Y., Tohira Y., Nishii Y., Suzuki M. 25-Hydroxylation of 1alpha-hydroxyvitamin D3 in vivo and in perfused rat liver. FEBS Lett 1976, 65:211-214.
5. Cheng J.B., Motola D.L., Mangelsdorf D.J., Russell D.W. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase. J Biol Chem 2003, 278:38084-38093.
6. Strushkevich N., Usanov S.A., Plotnikov A.N., Jones G., Park H.W. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol 2008, 380:95-106.
7. Casella S.J., Reiner B.J., Chen T.C., Holick M.F., Harrison H.E. A possible genetic defect in 25-hydroxylation as a cause of rickets. J Pediatr 1994, 124:929-932.
8. Cheng J.B., Levine M.A., Bell N.H., Mangelsdorf D.J., Russell D.W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 2004, 101:7711-7715.
9. Fraser D., Kooh S.W., Kind H.P., Holick M.F., Tanaka Y., DeLuca H.F. Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 1973, 289:817-822.
10. Okuda K.I., Usui E., Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. J Lipid Res 1995, 36:1641-1652.
11. Rosen H., Reshef A., Maeda N., et al. Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J Biol Chem 1998, 273:14805-14812.
12. Salen G., Shefer S., Cheng F.W., Dayal B., Batta A.K., Tint G.S. Cholic acid biosynthesis: the enzymatic defect in cerebrotendinous xanthomatosis. J Clin Invest 1979, 63:38-44.
13. Cali J.J., Hsieh C.L., Francke U., Russell D.W. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 1991, 266:7779-7783.
14. Kuriyama M., Fujiyama J., Kubota R., Nakagawa M., Osame M. Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 1993, 42:1497-1498.
15. Cali J.J., Russell D.W. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reactions in bile acid biosynthesis. J Biol Chem 1991, 266:7774-7778.
16. Andersson D., Davis D.L., Dahlback H., Jornvall H. Cloning, structure and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem 1989, 264:8222-8229.
17. Fu G.K., Lin D., Zhang M.Y., et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997, 11:1961-1970.
18. St-Arnaud R., Messerlian S., Moir J.M., Omdahl J.L., Glorieux F.H. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997, 12:1552-1559.
19. Shinki T., Shimada H., Wakino S., et al. Cloning and expression of rat 25-hydroxyvitamin D3-1alpha-hydroxylase cDNA. Proc Natl Acad Sci USA 1997, 94:12920-12925.
20. Takeyama K., Kitanaka S., Sato T., Kobori M., Yanagisawa J., Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997, 277:1827-1830.
21. Hasemann C.A., Kurumbail R.G., Boddupalli S.S., Peterson J.A., Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995, 3:41-62.
22. Ohyama Y., Noshiro M., Okuda K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS Lett 1991, 278:195-198.
23. Chung B.C., Matteson K.J., Voutilainen R., Mohandas T.K., Miller W.L. Human cholesterol side-chain cleavage enzyme, P450scc: cDNA cloning, assignment of the gene to chromosome 15, and expression in the placenta. Proc Natl Acad Sci USA 1986, 83:8962-8966.
24. Mornet E., Dupont J., Vitek A., White P.C. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 1989, 264:20961-20967.
25. Panda D.K., Al Kawas S., Seldin M.F., Hendy G.N., Goltzman D. 25-hydroxyvitamin D 1alpha-hydroxylase: structure of the mouse gene, chromosomal assignment, and developmental expression. J Bone Miner Res 2001, 16:46-56.
26. Fu G.K., Portale A.A., Miller W.L. Complete structure of the human gene for the vitamin D 1alpha- hydroxylase, P450c1alpha. DNA Cell Biol 1997, 16:1499-1507.
27. Kitanaka S., Takeyama K., Murayama A., et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998, 338:653-661.
28. Yoshida T., Monkawa T., Tenenhouse H.S., et al. Two novel 1alpha-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I. Kidney Int 1998, 54:1437-1443.
29. Labuda M., Morgan K., Glorieux F.H. Mapping autosomal recessive vitamin D dependency type I to chromosome 12q14 by linkage analysis. Am J Hum Genet 1990, 47:28-36.
30. Labuda M., Labuda D., Korab-Laskowska M., et al. Linkage disequilibrium analysis in young populations: pseudo-vitamin D- deficiency rickets and the founder effect in French Canadians. Am J Hum Genet 1996, 59:633-643.
31. Portale A.A., Miller W.L. Human 25-hydroxyvitamin D-1alpha-hydroxylase: cloning, mutations, and gene expression. Pediatr Nephrol 2000, 14:620-625.
32. Dardenne O., Prud'homme J., Arabian A., Glorieux F.H., St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)- hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001, 142:3135-3141.
33. Panda D.K., Miao D., Tremblay M.L., et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 2001, 98:7498-7503.
34. Yamagata M., Kimoto A., Michigami T., Nakayama M., Ozono K. Hydroxylases involved in vitamin D metabolism are differentially expressed in murine embryonic kidney: application of whole mount in situ hybridization. Endocrinology 2001, 142:3223-3230.
35. Puzas J.E., Turner R.T., Howard G.A., Brand J.S., Baylink D.J. Synthesis of 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol by calvarial cells. Characterization of the enzyme systems. Biochem J 1987, 245:333-338.
36. Reichel H., Bishop J.E., Koeffler H.P., Norman A.W. Evidence for 1,25-dihydroxyvitamin D3 production by cultured porcine alveolar macrophages. Mol Cell Endocrinol 1991, 75:163-167.
37. Fraser D.R., Kodicek E. Regulation of 25-hydroxycholecalciferol-1-hydroxylase activity in kidney by parathyroid hormone. Nat New Biol 1973, 241:163-166.
38. Murayama A., Takeyama K., Kitanaka S., Kodera Y., Hosoya T., Kato S. The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha,25(OH)2D3. Biochem Biophys Res Commun 1998, 249:11-16.
39. Brenza H.L., Kimmel-Jehan C., Jehan F., et al. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha- hydroxylase gene promoter. Proc Natl Acad Sci USA 1998, 95:1387-1391.
40. Horiuchi N., Suda T., Takahashi H., Shimazawa E., Ogata E. In vivo evidence for the intermediary role of 3′,5′-cyclic AMP in parathyroid hormone-induced stimulation of 1alpha,25-dihydroxyvitamin D3 synthesis in rats. Endocrinology 1977, 101:969-974.
41. Henry H.L. Parathyroid hormone modulation of 25-hydroxyvitamin D3 metabolism by cultured chick kidney cells is mimicked and enhanced by forskolin. Endocrinology 1985, 116:503-510.
42. Gao X.H., Dwivedi P.P., Choe S., et al. Basal and parathyroid hormone induced expression of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene promoter in kidney AOK-B50 cells: role of Sp1, Ets and CCAAT box protein binding sites. Int J Biochem Cell Biol 2002, 34:921-930.
43. Kim M.S., Kondo T., Takada I., et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009, 461:1007-1012.
44. Hendrich B., Hardeland U., Ng H.H., Jiricny J., Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 1999, 401:301-304.
45. Horiuchi N., Takahashi H., Matsumoto T., et al. Salmon calcitonin-induced stimulation of 1 alpha,25-dihydroxycholecalciferol synthesis in rats involving a mechanism independent of adenosine 3′:5′-cyclic monophosphate. Biochem J 1979, 184:269-275.
46. Galante L., Colston K.W., MacAuley S.J., MacIntyre I. Effect of calcitonin on vitamin D metabolism. Nature 1972, 238:271-273.
47. Shinki T., Ueno Y., DeLuca H.F., Suda T. Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci USA 1999, 96:8253-8258.
48. Friedlander E.J., Henry H.L., Norman A.W. Studies on the mode of action of calciferol. Effects of dietary calcium and phosphorus on the relationship between the 25-hydroxyvitamin D3-1alpha-hydroxylase and production of chick intestinal calcium binding protein. J Biol Chem 1977, 252:8677-8683.
49. Heaney R.P. Vitamin D: role in the calcium economy. Vitamin D 1997, 485-498. Academic Press, SanDiego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
50. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008, 118:3820-3828.
51. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21:1187-1196.
52. Bai X.Y., Miao D., Goltzman D., Karaplis A.C. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003, 278:9843-9849.
53. Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010, 61:91-104.
54. Henry H.L. Regulation of the hydroxylation of 25-hydroxyvitamin D3 in vivo and in primary cultures of chick kidney cells. J Biol Chem 1979, 254:2722-2729.
55. Booth B.E., Tsai H.C., Morris R.C. Vitamin D status regulates 25-hydroxyvitamin D3-1 alpha-hydroxylase and its responsiveness to parathyroid hormone in the chick. J Clin Invest 1985, 75:155-161.
56. Demay M.B., Kiernan M.S., DeLuca H.F., Kronenberg H.M. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1992, 89:8097-8101.
57. Murayama A., Takeyama K., Kitanaka S., et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology 1999, 140:2224-2231.
58. Silver J., Naveh-Many T., Mayer H., Schmelzer H.J., Popovtzer M.M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986, 78:1296-1301.
59. Kato S., Kim M.S., Yamaoka K., Fujiki R. Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D. Curr Opin Nephrol Hypertens 2007, 16:297-304.
60. Kim M.S., Fujiki R., Kitagawa H., Kato S. 1alpha,25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol 2007, 265-266:168-173.
61. Murayama A., Takeyama K., Asahina T., Kitanaka S., Kato S. Cloning of a novel transcription factor mediating the negative vitamin D responsiveness through the human 25-hydroxyvitamin D-1alpha-hydroxylase nVDRE. J Bone Miner Res 2000, 15:S199.
62. Murayama A., Kim M.S., Yanagisawa J., Takeyama K., Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. Embo J 2004, 23:1598-1608.
63. Ohyama Y., Hayashi S., Okuda K. Purification of 25-hydroxyvitamin D3 24-hydroxylase from rat kidney mitochondria. FEBS Lett 1989, 255:405-408.
64. Ohyama Y., Okuda K. Isolation and characterization of a cytochrome P-450 from rat kidney mitochondria that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3. J Biol Chem 1991, 266:8690-8695.
65. Chen K.S., DeLuca H.F. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995, 1263:1-9.
66. Hahn C.N., Kerry D.M., Omdahl J.L., May B.K. Identification of a vitamin D responsive element in the promoter of the rat cytochrome P450(24) gene. Nucleic Acids Res 1994, 22:2410-2416.
67. Ohyama Y., Noshiro M., Eggertsen G., et al. Structural characterization of the gene encoding rat 25-hydroxyvitamin D3 24-hydroxylase. Biochemistry 1993, 32:76-82.
68. Tanaka Y., Castillo L., DeLuca H.F. The 24-hydroxylation of 1,25-dihydroxyvitamin D3. J Biol Chem 1977, 252:1421-1424.
69. Tanaka Y., DeLuca H.F. Stimulation of 24,25-dihydroxyvitamin D3 production by 1,25-dihydroxyvitamin D3. Science 1974, 183:1198-1200.
70. Napoli J.L., Horst R.L. C(24)- and C(23)-oxidation, converging pathways of intestinal 1,25-dihydroxyvitamin D3 metabolism: identification of 24-keto-1,23,25-trihydroxyvitamin D3. Biochemistry 1983, 22:5848-5853.
71. Ohnuma N., Norman A.W. Identification of a new C-23 oxidation pathway of metabolism for 1,25-dihydroxyvitamin D3 present in intestine and kidney. J Biol Chem 1982, 257:8261-8271.
72. Takasaki Y., Suda T., Yamada S., Takayama H., Nishii Y. Isolation, identification, and biological activity of 25-hydroxy-24-oxovitamin D3: a new metabolite of vitamin D3 generated by in vitro incubations with kidney homogenates. Biochemistry 1981, 20:1681-1686.
73. Jones G., Kano K., Yamada S., Furusawa T., Takayama H., Suda T. Identification of 24,25,26,27-tetranor-23-hydroxyvitamin D3 as a product of the renal metabolism of 24,25-dihydroxyvitamin D3. Biochemistry 1984, 23:3749-3754.
74. Makin G., Lohnes D., Byford V., Ray R., Jones G. Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 1989, 262:173-180.
75. Reddy G.S., Tserng K.Y. Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through C-24 oxidation pathway. Biochemistry 1989, 28:1763-1769.
76. Esvelt R.P., Schnoes H.K., DeLuca H.F. Isolation and characterization of 1 alpha-hydroxy-23-carboxytetranorvitamin D: a major metabolite of 1,25-dihydroxyvitamin D3. Biochemistry 1979, 18:3977-3983.
77. Kumar R., Schaefer J., Grande J.P., Roche P.C. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am J Physiol 1994, 266:F477-F485.
78. Kawashima H., Torikai S., Kurokawa K. Localization of 25-hydroxyvitamin D3 1 alpha-hydroxylase and 24-hydroxylase along the rat nephron. Proc Natl Acad Sci USA 1981, 78:1199-1203.
79. Akeno N., Saikatsu S., Kawane T., Horiuchi N. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3. Endocrinology 1997, 138:2233-2240.
80. Masuda S., Strugnell S., Calverley M.J., Makin H.L., Kremer R., Jones G. In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J Biol Chem 1994, 269:4794-4803.
81. Tomon M., Tenenhouse H.S., Jones G. Expression of 25-hydroxyvitamin D3-24-hydroxylase activity in Caco-2 cells. An in vitro model of intestinal vitamin D catabolism. Endocrinology 1990, 126:2868-2875.
82. Reinhardt T.A., Horst R.L. Self-induction of 1,25-dihydroxyvitamin D3 metabolism limits receptor occupancy and target tissue responsiveness. J Biol Chem 1989, 264:15917-15921.
83. Sakaki T., Sawada N., Komai K., et al. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem/FEBS 2000, 267:6158-6165.
84. Prosser D.E., Kaufmann M., O'Leary B., Byford V., Jones G. Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone. Proc Natl Acad Sci USA 2007, 104:12673-12678.
85. Akiyoshi-Shibata M., Sakaki T., Ohyama Y., Noshiro M., Okuda K., Yabusaki Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. Eur J Biochem/FEBS 1994, 224:335-343.
86. Beckman M.J., Tadikonda P., Werner E., Prahl J., Yamada S., DeLuca H.F. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996, 35:8465-8472.
87. Reinhardt T.A., Horst R.L. Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells. Arch Biochem Biophys 1989, 272:459-465.
88. St-Arnaud R., Arabian A., Travers R., et al. Deficient mineralization of intramembranous bone in vitamin D-24- hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141:2658-2666.
89. Annalora A.J., Goodin D.B., Hong W.X., Zhang Q., Johnson E.F., Stout C.D. Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. J Mol Biol 2010, 396:441-451.
90. Engstrom G.W., Reinhardt T.A., Horst R.L. 25-Hydroxyvitamin D3-23-hydroxylase, a renal enzyme in several animal species. Arch Biochem Biophys 1986, 250:86-93.
91. Sakaki T., Sawada N., Nonaka Y., Ohyama Y., Inouye K. Metabolic studies using recombinant Escherichia coli cells producing rat mitochondrial CYP24. CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid. Eur J Biochem/FEBS 1999, 262:43-48.
92. Kahraman M., Sinishtaj S., Dolan P.M., et al. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). J Med Chem 2004, 47:6854-6863.
93. Schuster I., Egger H., Nussbaumer P., Kroemer R.T. Inhibitors of vitamin D hydroxylases: structure-activity relationships. J Cell Biochem 2003, 88:372-380.
94. Schuster I., Egger H., Reddy G.S., Vorisek G. Combination of vitamin D metabolites with selective inhibitors of vitamin D metabolism. Recent Results Cancer Res 2003, 164:169-188.
95. Schuster I., Egger H., Herzig G., et al. Selective inhibitors of vitamin D metabolism - new concepts and perspectives. Anticancer Res 2006, 26:2653-2668.
96. Annalora A., Bobrovnikova-Marjon E., Serda R., et al. Rat cytochrome P450C24 (CYP24A1) and the role of F249 in substrate binding and catalytic activity. Arch Biochem Biophys 2004, 425:133-146.
97. Omdahl J.L., Swamy N., Serda R., Annalora A., Berne M., Rayb R. Affinity labeling of rat cytochrome P450C24 (CYP24) and identification of Ser57 as an active site residue. J Steroid Biochem Mol Biol 2004, 89-90:159-162.
98. Makishima M., Lu T.T., Xie W., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
99. Bartik L., Whitfield G.K., Kaczmarska M., et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem 2010.
100. Skorija K., Cox M., Sisk J.M., et al. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol 2005, 19:855-862.
101. Haussler M.R., Whitfield G.K., Haussler C.A., et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998, 13:325-349.
102. Baker A.R., McDonnell D.P., Hughes M., et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988, 85:3294-3298.
103. Li Y.C., Bergwitz C., Juppner H., Demay M. Cloning and characterization of the vitamin D receptor from Xenopus laevis. Endocrinology 1997, 138:2347-2353.
104. Whitfield G.K., Dang H.T., Schluter S.F., et al. Cloning of a functional vitamin D receptor from the lamprey (Petromyzon marinus), an ancient vertebrate lacking a calcified skeleton and teeth. Endocrinology 2003, 144:2704-2716.
105. Jurutka P.W., Hsieh J.C., MacDonald P.N., et al. Phosphorylation of serine 208 in the human vitamin D receptor. The predominant amino acid phosphorylated by casein kinase II, in vitro, and identification as a significant phosphorylation site in intact cells. J Biol Chem 1993, 268:6791-6799.
106. Hilliard G.M.T., Cook R.G., Weigel N.L., Pike J.W. 1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. Biochemistry 1994, 33:4300-4311.
107. Jurutka P.W., Hseih J.-C., Nakajima S., Haussler C.A., Haussler M. Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. Proc Natl Acad Sci USA 1996, 93:3519-3524.
108. Arriagada G., Paredes R., Olate J., et al. Phosphorylation at serine 208 of the 1alpha,25-dihydroxy vitamin D3 receptor modulates the interaction with transcriptional coactivators. J Steroid Biochem Mol Biol 2007, 103:4259.
109. Hsieh J.C., Dang H.T., Galligan M.A., et al. Phosphorylation of human vitamin D receptor serine-182 by PKA suppresses 1,25(OH)2D3-dependent transactivation. Biochem Biophys Res Commun 2004, 324:801-809.
110. Hsieh J.C., Jurutka P.W., Galligan M.A., et al. Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function. Proc Natl Acad Sci USA 1991, 88:9315-9319.
111. Hsieh J.C., Jurutka P.W., Nakajima S., et al. Phosphorylation of the human vitamin D receptor by protein kinase C. Biochemical and functional evaluation of the serine 51 recognition site. J Biol Chem 1993, 268:15118-15126.
112. MacDonald P.N., Sherman D.R., Dowd D.R., Jefcoat S.C., DeLisle R.K. The vitamin D receptor interacts with general transcription factor IIB. J Biol Chem 1995, 270:4748-4752.
113. McKenna N., Xu J., Nawaz Z., Tsai S., Tsai M., O'Malley B. Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Molec Biol 1999, 69:3-12.
114. Onate S., Tsai S., Tsai M., O'Malley B. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
115. Kraichely D., Collins J., DeLisle R., MacDonald P.N. The autonomous transactivation domain in helix H3 of the vitamin D receptor is required for transactivation and coactivator interaction. J Biol Chem 1999, 274:14352-14358.
116. Yanagisawa J., Yanagi Y., Masuhiro Y., et al. Convergence of transforming growth factor beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
117. Takeshita A., Yen P., Misiti S., Cardona G., Liu Y., Chin W. Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology 1996, 137:3594-3597.
118. Spencer T., Jenster G., Burcin M., et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997, 389:194-198.
119. Bannister A., Kouzarides T. The CBP coactivator is a histone acetyl transferease. Nature 1996, 384:641-643.
120. Baudino T.A., Kraichely D.M., Jefcoat S.C., et al. Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem 1998, 273:16434-16441.
121. Barry J.B., Leong G.M., Church W.B., Issa L.L., Eisman J.A., Gardiner E.M. Interactions of SKIP/NCoA-62, TFIIB, and retinoid X receptor with vitamin D receptor helix H10 residues. J Biol Chem 2003, 278:8224-8228.
122. Rachez C., Suldan Z., Ward J., et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 1998, 12:1787-1800.
123. Rachez C., Lemon B., Suldan Z., et al. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999, 398:824-828.
124. Chiba N., Suldan Z., Freedman L.P., Parvin J. Binding of liganded vitamin D receptor to the vitamin D receptor interacting protein coactivator complex induces interaction with RNA polymerase II holoenzyme. J Biol Chem 2000, 275:10719-10722.
125. Oda Y., Ishikawa M.H., Hawker N.P., Yun Q.C., Bikle D.D. Differential role of two VDR coactivators, DRIP205 and SRC-3, in keratinocyte proliferation and differentiation. J Steroid Biochem Mol Biol 2007, 103:776-780.
126. Sanchez-Martinez R., Zambrano A., Castillo A.I., Aranda A. Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. Mol Cell Biol 2008, 28:3817-3829.
127. Hsieh J.C., Sisk J.M., Jurutka P.W., et al. Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. J Biol Chem 2003, 278:38665-38674.
128. Ahmad W., Faiyaz ul Haque M., Brancolini V., et al. Alopecia universalis associated with a mutation in the human hairless gene. Science 1998, 279:720-724.
129. Marx S.J., Bliziotes M.M., Nanes M. Analysis of the relation between alopecia and resistance to 1,25-dihydroxyvitamin D. Clin Endocrinol 1986, 25:373-381.
130. Demay M.B., Kiernan M.S., DeLuca H.F., Kronenberg H.M. Characterization of 1,25-dihydroxyvitamin D3 receptor interactions with target sequences in the rat osteocalcin gene. Mol Endocrinol 1992, 6:557-562.
131. 3 receptors. Cell 1991, 65:1255-1266.
132. 3. Proc Natl Acad Sci USA 1990, 87:369-373.
133. Ozono K., Liao J., Kerner S.A., Scott R.A., Pike J.W. The vitamin D-responsive element in the human osteocalcin gene: association with a nuclear proto-oncogene enhancer. J Biol Chem 1990, 265:21881-21888.
134. 3 enhancement of mouse secreted phosphoprotein 1 (Spp-1 or osteopontin) gene expression. Proc Natl Acad Sci USA 1990, 87:9995-9999.
135. 3. J Biol Chem 1993, 268:27371-27380.
136. 3. J Biol Chem 1993, 268:1456-1461.
137. Kerry D.M., Dwivedi P.P., Hahn C.N., Morris H.A., Omdahl J.L., May B.K. Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) promoter. J Biol Chem 1996, 271:29715-29721.
138. Ohyama Y., Ozono K., Uchida M., et al. Identification of a vitamin D-responsive element in the 5′-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J Biol Chem 1994, 269:10545-10550.
139. Darwish H.M., DeLuca H.F. Identification of a 1,25-dihydroxyvitamin D3-response element in the 5′-flanking region of the rat calbindin D-9k gene. Proc Natl Acad Sci USA 1992, 89:603-607.
140. 3- and butyrate-inducible responses. Proc Natl Aca Sci USA 1993, 90:2984-2988.
141. Dupret J.M., L'Horset F., Perret C., Bernaudin J.-F., Thomasset M. Calbindin-D9K gene expression in the lung of the rat. Absence of regulation by 1,25-dihydroxyvitamin D3 and estrogen. Endocrinology 1992, 131:2643-2648.
142. Glazier J.D., Mawer E.B., Sibley C.P. Calbindin-D9k gene expression in rat chorioallantoic placenta is not regulated by 1,25-dihydroxyvitamin D3. Pediatr Res 1995, 37:720-725.
143. Colnot S., Ovejero C., Romagnolo B., et al. Transgenic analysis of the response of the rat calbindin-D 9k gene to vitamin D. Endoocrinology 2000, 141:2301-2308.
144. Candeliere G.A., Jurutka P.W., Haussler M.R., St-Arnaud R. A composite element binding the vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the c-fos promoter. Mol Cell Biol 1996, 16:584-592.
145. Meyer M.B., Goetsch P.D., Pike J.W. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem 2010, 285:15599-15610.
146. Liu S.M., Koszewski N., Lupez M., Malluche H.H., Olivera A., Russell J. Characterization of a response element in the 5′-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor. Mol Endocrinol 1996, 10:206-215.
147. Mackey S.L., Heymont J.L., Kronenberg H.M., Demay M.B. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Mol Endocrinol 1996, 10:298-305.
148. Kim M.S., Fujiki R., Murayama A., et al. 1Alpha,25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol Endocrinol 2007, 21:334-342.
149. Nishishita T., Okazaki T., Ishikawa T., et al. A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J Biol Chem 1998, 273:10901-10907.
150. Yen P., Liu Y., Sugawara A., Chin W. Vitamin D receptors repress basal transcription and exert dominant negative activity on triiodothyronine-mediated transcriptional activity. J Biol Chem 1996, 271:10910-10916.
151. Sakai Y., Kishimoto J., Demay M.B. Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J Clin Invest 2001, 107:961-966.
152. Kitagawa H., Fujiki R., Yoshimura K., et al. The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 2003, 113:905-917.
153. Barsony J., Marx S. Rapid accumulation of cyclic GMP near activated vitamin D receptors. Proc Natl Acad Sci USA 1991, 88:1436-1440.
154. Civitelli R., Kim Y.S., Gunsten S.L., et al. Nongenomic activation of the calcium message system by vitamin D metabolites in osteoblast-like cells. Endocrinology 1990, 127:2253-2262.
155. 2+-Channel agonist bay K8644 mimics 1,25(OH)2-vitamin D3 rapid enhancement of Ca2+ transport in chick perfused duodenum. Biochem Biophys Res Commun 1990, 166:217-222.
156. 3 in rat osteosarcoma cells: structure-function studies using ligand analogs. Endocrinology 1991, 129:1876-1884.
157. Schwartz Z., Brooks B., Swain L., Del Toro F., Norman A., Boyan B. Production of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by growth zone and resting zone chondrocytes is dependent on cell maturation and is regulated by hormones and growth factors. Endocrinology 1992, 130:2495-2504.
158. Schwartz Z., Sylvia V.L., Luna M.H., et al. The effect of 24R,25-(OH)(2)D(3) on protein kinase C activity in chondrocytes is mediated by phospholipase D whereas the effect of 1alpha,25-(OH)(2)D(3) is mediated by phospholipase C. Steroids 2001, 66:683-694.
159. Erben R.G., Soegiarto D.W., Weber K., et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 2002, 16:1524-1537.
160. Khanal R.C., Nemere I. The ERp57/GRp58/1,25D3-MARRS receptor: multiple functional roles in diverse cell systems. Curr Med Chem 2007, 14:1087-1093.
161. Halloran B.P., DeLuca H.F. Effect of vitamin D deficiency on skeletal development during early growth in the rat. Arch Biochem Biophys 1981, 209:7-14.
162. Peacock M., Selby P.L., Francis R.M., Brown W.B., Hordon L. Vitamin D deficiency, insufficiency, sufficiency, and intoxication: what do they
163. Pettifor M.P., Daniels E.D. Vitamin D Deficiency and Nutritional Rickets in Children 1997, Academic Press, San Diego, CA.
164. Thomas M.K., Demay M.B. Vitamin D deficiency and disorders of vitamin D metabolism. Endocrinol Metab Clin North Am 2000, 29:611-627. viii.
165. 3 of cell proliferation and function of bovine parathyroid cells in culture. J Bone Miner Res 1990, 5:755-760.
166. 3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986, 119:2864-2866.
167. Silver J., Russell J., Sherwood L.M. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985, 82:4270-4273.
168. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989, 35:1049-1056.
169. Dardenne O., Prud'homme J., Hacking S.A., Glorieux F.H., St-Arnaud R. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). Bone 2003, 32:332-340.
170. Li Y.C., Amling M., Pirro A.E., et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998, 139:4391-4396.
171. Al-Aqeel A., Ozand P., Sobki S., Sewairi W., Marx S. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII). Clin Endocrinol 1993, 39:229-237.
172. Amling M., Priemel M., Holzmann T., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
173. Balsan S., Garabedian M., Larchet M., et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986, 77:1661-1667.
174. Weinstein R.S., Underwood J.L., Hutson M.S., DeLuca H.F. Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus. Am J Physiol 1984, 246:E499-E506.
175. Donohue M.M., Demay M.B. Rickets in VDR null mice is secondary to decreased apoptosis of hypertrophic chondrocytes. Endocrinology 2002, 143:3691-3694.
176. Sabbagh Y., Carpenter T.O., Demay M.B. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci USA 2005, 102:9637-9642.
177. 3 inhibits transcription of type I collagen genes in the rat osteosarcoma line ROS 17/2.8. Endocrinology 1989, 125:327-333.
178. Wientroub S., Fisher L., Reddi A., Termine J. Noncollagenous bone proteins in experimental rickets in the rat. Mol Cell Biochem 1987, 74:157-162.
179. Underwood J.L., DeLuca H.F. Vitamin D is not directly necessary for bone growth and mineralization. Am J Physiol 1984, 246:E493-E498.
180. Takeda S., Yoshizawa T., Nagai Y., et al. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 1999, 140:1005-1008.
181. Hoenderop J., VanDerKemp A., Hartog A., et al. Molecular identification of the apical Ca2+ channel in 1,25-dihydroxyvitamin D-responsive epithelia. J Biol Chem 1999, 274:8375-8378.
182. Peng J., Chen X., Berger U., et al. Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem 1999, 274:22739-22746.
183. Hoenderop J.G., van Leeuwen J.P., van der Eerden B.C., et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003, 112:1906-1914.
184. Wasserman R.H., Fullmer C.S. Calcium transport proteins, calcium absorption, and vitamin D. Ann Rev Physiol 1983, 45:375-390.
185. Benn B.S., Ajibade D., Porta A., et al. Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology 2008, 149:3196-3205.
186. Fujita H., Sugimoto K., Inatomi S., et al. Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol Biol Cell 2008, 19:1912-1921.
187. Manolagas S.C., Yu X.-P., Girasole G., Bellido T. Vitamin D and the hematolymphopoietic tissue: a 1994 update. Semin Nephrol 1994, 14:129-143.
188. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chanders S., Coombes R.C. EB 1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 1992, 44:2273-2280.
189. Colston K.W., Perks C.M., Xie S.P., Holly J.M. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998, 20:157-162.
190. Feldman D., Skowronski R.J., Peehl D.M. Vitamin D and prostate cancer. Adv Exp Med Biol 1996, 375:53-63.
191. Bikle D.D., Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev 1993, 14:3-19.
192. Sorensen S., Solvsten H., Politi Y., Kragballe K. Effects of vitamin D3 on keratinocyte proliferation and differentiation in vitro: modulation by ligands for retinoic acid and retinoid X receptors. Skin Pharmacol 1997, 10:144-152.
193. Su M.J., Bikle D.D., Mancianti M.L., Pillai S. 1,25-Dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. J Biol Chem 1994, 269:14723-14729.
194. 3) for treatment of psoriasis. Arch Dermatol 1987, 123:1677-1683.
195. Bischoff-Ferrari H.A. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008, 624:55-71.
196. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
197. Powell S.M., Zilz N., Beazer-Barclay Y., et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235-237.
198. Palmer H.G., Sanchez-Carbayo M., Ordonez-Moran P., Larriba M.J., Cordon-Cardo C., Munoz A. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res 2003, 63:7799-7806.
199. Usui E., Noshiro M., Okuda K. Molecular cloning of cDNA for vitamin D3 25-hydroxylase from rat liver mitochondria. FEBS Lett 1990, 262:135-138.
200. Su P., Rennert H., Shayiq R.M., et al. A cDNA encoding a rat mitochondrial cytochrome P450 catalyzing both the 26-hydroxylation of cholesterol and 25-hydroxylation of vitamin D3: gonadotropic regulation of the cognate mRNA in ovaries. DNA Cell Biol 1990, 9:657-667.
201. Repa J.J., Lund E.G., Horton J.D., et al. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J Biol Chem 2000, 275:39685-39692.
202. Cooke N.E., Haddad J.G. Vitamin D binding protein (Gc-globulin). Endocr Rev 1989, 10:294-307.
203. Safadi F.F., Thornton P., Magiera H., et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999, 103:239-251.
204. Verroust P.J., Kozyraki R. The roles of cubilin and megalin, two multiligand receptors, in proximal tubule function: possible implication in the progression of renal disease. Curr Opin Nephrol Hypertens 2001, 10:33-38.
205. Barth J.L., Argraves W.S. Cubilin and megalin: partners in lipoprotein and vitamin metabolism. Trends Cardiovasc Med 2001, 11:26-31.
206. Willnow T.E., Hilpert J., Armstrong S.A., et al. Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci USA 1996, 93:8460-8464.
207. Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
208. Bikle D.D., Gee E., Halloran B., Kowalski M.A., Ryzen E., Haddad J.G. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986, 63:954-959.
209. Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. Biol Chem 1998, 379:951-964.
210. Moestrup S.K., Kozyraki R., Kristiansen M., et al. The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem 1998, 273:5235-5242.
211. Nykjaer A., Fyfe J.C., Kozyraki R., et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci USA 2001, 98:13895-13900.
212. St-Arnaud R. Targeted inactivation of vitamin D hydroxylases in mice. Bone 1999, 25:127-129.
213. Masuda S., Kaufmann M., Byford V., et al. Insights into Vitamin D metabolism using cyp24 over-expression and knockout systems in conjunction with liquid chromatography/mass spectrometry (LC/MS). J Steroid Biochem Mol Biol 2004, 89-90:149-153.
214. Masuda S., Byford V., Arabian A., et al. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005, 146:825-834.
215. Miyamoto Y., Shinki T., Yamamoto K., et al. 1alpha,25-dihydroxyvitamin D3-24-hydroxylase (CYP24) hydroxylates the carbon at the end of the side chain (C-26) of the C-24-fluorinated analog of 1alpha,25-dihydroxyvitamin D3. J Biol Chem 1997, 272:14115-14119.
216. St-Arnaud R., Glorieux F.H. Vitamin D and bone development. Vitamin D 1997, 293-303. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
217. Li Y.C., Pirro A.E., Amling M., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997, 94:9831-9835.
218. Miller W.L., Portale A.A. Genetic causes of rickets. Curr Opin Pediatr 1999, 11:333-339.
219. St-Arnaud R., Glorieux F.H. Endocrinology. Hereditary defects in vitamin D metabolism and action 2000, Vol. 2:1154-1168. W.B. Saunders Company, Philadelphia. 4th ed. L.J. DeGroot, J.L. Jameson (Eds.).
220. Schipani E. Conditional gene inactivation using cre recombinase. Calcif Tissue Int 2002, 71:100-102.
221. Delvin E.E., Glorieux F.H., Marie P.J., Pettifor J.M. Vitamin D dependency: replacement therapy with calcitriol. J Pediatr 1981, 99:26-34.
222. Rosen J.F., Finberg L. Vitamin D-dependent rickets: actions of parathyroid hormone and 25-hydroxycholecalciferol. Pediatr Res 1972, 6:552-562.
223. Scriver C.R., Reade T.M., DeLuca H.F., Hamstra A.J. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 1978, 299:976-979.
224. Mandla S., Jones G., Tenenhouse H.S. Normal 24-hydroxylation of vitamin D metabolites in patients with vitamin D-dependency rickets type I. Structural implications for the vitamin D hydroxylases. J Clin Endocrinol Metab 1992, 74:814-820.
225. St-Arnaud R., Dardenne O., Glorieux F.H. Etiologie moléculaire des rachitismes vitamino-dépendents héréditaires. Méd/Sci 2001, 17:1289-1296.
226. Glorieux F.H., St-Arnaud R. Vitamin D pseudodeficiency. Vitamin D 1997, 755-764. Academic Press, SanDiego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
227. Dardenne O., Prudhomme J., Hacking S.A., Glorieux F.H., St-Arnaud R. Rescue of the pseudo-vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyvitamin D3: biochemical, histomorphometric, and biomechanical analyses. J Bone Miner Res 2003, 18:637-643.
228. Naja R.P., Dardenne O., Arabian A. St Arnaud R. Chondrocyte-specific modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate development. Endocrinology 2009, 150:4024-4032.
229. Masuyama R., Stockmans I., Torrekens S., et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006, 116:3150-3159.
230. Yoshizawa T., Handa Y., Uematsu Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997, 16:391-396.
231. Van Cromphaut S.J., Dewerchin M., Hoenderop J.G., et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci USA 2001, 98:13324-13329.
232. 3 on duodenal calcium absorption in vivo during early development. Am J Physiol 1984, 246:G528-G534.
233. Tu Q., Pi M., Karsenty G., Simpson L., Liu S., Quarles L.D. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 2003, 111:1029-1037.
234. Miedlich S.U., Zalutskaya A., Zhu E.D., Demay M.B. Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon Erk1/2 phosphorylation. J Biol Chem 2010, 285:18270-18275.
235. Baker M.R., McDonnell H., Peacock M., Nordin B.E. Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck. Br Med J 1979, 1:589.
236. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992, 327:1637-1642.
237. Lips P., Graafmans W.C., Ooms M.E., Bezemer P.D., Bouter L.M. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 1996, 124:400-406.
238. Pavlovitch J.H., Galoppin L., Rizk M., Didierjean L., Balsan S. Alterations in rat epidermis provoked by chronic vitamin D deficiency. Am J Physiol 1984, 247:E228-E233.
239. Sakai Y., Demay M.B. Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 2000, 141:2043-2049.
240. Xie Z., Komuves L., Yu Q.C., et al. Lack of the vitamin D receptor is associated with reduced epidermal differentiation and hair follicle growth. J Invest Dermatol 2002, 118:11-16.
241. Cianferotti L., Cox M., Skorija K., Demay M.B. Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc Natl Acad Sci USA 2007, 104:9428-9433.
242. Palmer H.G., Anjos-Afonso F., Carmeliet G., Takeda H., Watt F.M. The vitamin D receptor is a Wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS One 2008, 3:e1483.
243. Li M., Chiba H., Warot X., et al. RXR-alpha ablation in skin keratinocytes results in alopecia and epidermal alterations. Development 2001, 128:675-688.
244. Beaudoin G.M., Sisk J.M., Coulombe P.A., Thompson C.C. Hairless triggers reactivation of hair growth by promoting Wnt signaling. Proc Natl Acad Sci USA 2005, 102:14653-14658.
245. Huelsken J., Vogel R., Erdmann B., Cotsarelis G., Birchmeier W. beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 2001, 105:533-545.
246. Mathieu C., Waer M., Laureys J., Rutgeerts O., Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994, 37:552-558.
247. Griffin M., Lutz W., Phan V., et al. Dendritic cell modulation by 1,25-dihydroxyvitamin D and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vivo and in vitro. Proc Natl Acad Sci USA 2001, 98:6800-6805.
248. Mathieu C., VanEtten E., Gysemans C., et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 2001, 16:2057-2065.
249. Meehan T.F., DeLuca H.F. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 2002, 408:200-204.
250. Froicu M., Cantorna M.T. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007, 8:5.
251. Wittke A., Chang A., Froicu M., et al. Vitamin D receptor expression by the lung micro-environment is required for maximal induction of lung inflammation. Arch Biochem Biophys 2007, 460:306-313.
252. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995, 16:200-257.
253. Boyan B.D., Sylvia V.L., Dean D.D., Schwartz Z. 24,25-(OH)(2)D(3) regulates cartilage and bone via autocrine and endocrine mechanisms. Steroids 2001, 66:363-374.
254. Boyan B.D., Sylvia V.L., Dean D.D., Del Toro F., Schwartz Z. Differential regulation of growth plate chondrocytes by 1alpha,25-(OH)2D3 and 24R,25-(OH)2D3 involves cell-maturation-specific membrane-receptor-activated phospholipid metabolism. Crit Rev Oral Biol Med 2002, 13:143-154.
255. Boyan B.D., Jennings E.G., Wang L., Schwartz Z. Mechanisms regulating differential activation of membrane-mediated signaling by 1alpha,25(OH)2D3 and 24R,25(OH)2D3. J Steroid Biochem Mol Biol 2004, 89-90:309-315.
256. 3 [24,25-(OH)2D3] induces differentiation into a 125-(OH)2D3-responsive phenotype characteristic of growth zone chondrocytes. Endocrinology 1995, 136:402-411.
257. 3. Vitamin D 2005, Vol. 1:575-597. Elsevier Academic Press, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
258. St-Arnaud R. Vitamin D. Mutant mouse models of vitamin D metabolic enzymes 2005, Vol. 1:105-116. Elsevier Academic Press, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
259. Seo E.G., Norman A.W. Three-fold induction of renal 25-hydroxyvitamin D3-24-hydroxylase activity and increased serum 24,25-dihydroxyvitamin D3 levels are correlated with the healing process after chick tibial fracture. J Bone Miner Res 1997, 12:598-606.
260. Seo E.G., Einhorn T.A., Norman A.W. 24R,25-dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks. Endocrinology 1997, 138:3864-3872.
261. Naja R.P. The role of vitamin D metabolic enzymes in bone development and repair. Ph.D. Thesis, Department of Human Genetics 2009, McGill, Montreal.
262. Erben R.G., Bante U., Birner H., Stangassinger M. Prophylactic effects of 1,24,25-trihydroxyvitamin D3 on ovariectomy-induced cancellous bone loss in the rat. Calcif Tissue Int 1997, 60:434-440.
263. Campbell M.J., Reddy G.S., Koeffler H.P. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 1997, 66:413-425.
264. Stern P.H., Rappaport M.S., Mayer E., Norman A.W. 24-Oxo and 26,23-lactone metabolites of 1,25-dihydroxyvitamin D3 have direct bone-resorbing activity. Arch Biochem Biophys 1984, 230:424-429.
265. Jones G. Analog metabolism. Vitamin D 1997, 973-994. Academic Press, San Diego, CA. D. Feldman, F. Glorieux, J. Pike (Eds.).
266. Ishizuka S., Ishimoto S., Norman A.W. Biological activity assessment of 1 alpha,25-dihydroxyvitamin D3-26,23-lactone in the rat. J Steroid Biochem 1984, 20:611-615.
267. Ishizuka S., Norman A.W. The difference of biological activity among four diastereoisomers of 1 alpha,25-dihydroxycholecalciferol-26,23-lactone. J Steroid Biochem 1986, 25:505-510.
268. Toell A., Gonzalez M.M., Ruf D., Steinmeyer A., Ishizuka S., Carlberg C. Different molecular mechanisms of vitamin D(3) receptor antagonists. Mol Pharmacol 2001, 59:1478-1485.
269. Ishizuka S., Kurihara N., Reddy S.V., Cornish J., Cundy T., Roodman G.D. (23S)-25-Dehydro-1α-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology 2005, 146:2023-2030.
270. Bischof M.G., Siu-Caldera M.L., Weiskopf A., et al. Differentiation-related pathways of 1 alpha,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1 alpha,25-dihydroxy-3epi-cholecalciferol. Exp Cell Res 1998, 241:194-201.
271. Brown A.J., Ritter C., Slatopolsky E., Muralidharan K.R., Okamura W.H., Reddy G.S. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. J Cell Biochem 1999, 73:106-113.
272. Astecker N., Reddy G.S., Herzig G., Vorisek G., Schuster I. 1alpha,25-Dihydroxy-3-epi-vitamin D3 a physiological metabolite of 1alpha,25-dihydroxyvitamin D3: its production and metabolism in primary human keratinocytes. Mol Cell Endocrinol 2000, 170:91-101.
273. Siu-Caldera M.L., Sekimoto H., Weiskopf A., et al. Production of 1alpha,25-dihydroxy-3-epi-vitamin D3 in two rat osteosarcoma cell lines (UMR 106 and ROS 17/2.8): existence of the C-3 epimerization pathway in ROS 17/2.8 cells in which the C-24 oxidation pathway is not expressed. Bone 1999, 24:457-463.
274. Rao D.S., Campbell M.J., Koeffler H.P., et al. Metabolism of 1alpha,25-dihydroxyvitamin D(3) in human promyelocytic leukemia (HL-60) cells: in vitro biological activities of the natural metabolites of 1alpha,25-dihydroxyvitamin D(3) produced in HL-60 cells. Steroids 2001, 66:423-431.
275. Sekimoto H., Siu-Caldera M.L., Weiskopf A., et al. 1alpha,25-dihydroxy-3-epi-vitamin D3: in vivo metabolite of 1alpha,25- dihydroxyvitamin D3 in rats. FEBS Lett 1999, 448:278-282.
276. Schuster I., Astecker N., Egger H., et al. Vitamin D-metabolism in human keratinocytes and biological role of products. Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone 1997, 551-558. University of California Press, Riverside, CA. A. Norman, R. Bouillon, M. Thomasset (Eds.).
277. 3. J Biol Chem 1993, 268:20022-20030.
278. Harant H., Spinner D., Reddy G.S., Lindley I.J. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J Cell Biochem 2000, 78:112-120.
279. Messerlian S., Gao X., St-Arnaud R. The 3-epi- and 24-oxo-derivatives of 1alpha,25 dihydroxyvitamin D(3) stimulate transcription through the vitamin D receptor. J Steroid Biochem Mol Biol 2000, 72:29-34.
280. Seo E.G., Kato A., Norman A.W. Evidence for a 24R,25(OH)2-vitamin D3 receptor/binding protein in a membrane fraction isolated from a chick tibial fracture-healing callus. Biochem Biophys Res Commun 1996, 225:203-208.
281. Kato A., Seo E.G., Einhorn T.A., Bishop J.E., Norman A.W. Studies on 24R,25-dihydroxyvitamin D3: evidence for a nonnuclear membrane receptor in the chick tibial fracture-healing callus. Bone 1998, 23:141-146.